Last reviewed · How we verify
NCT04031651
Key Specialized Monitoring of Clinical Safety of Pudilan Xiaoyan Oral Liquid in the Real World
trial testing Pudilan Xiaoyan Oral Liquid in Respiratory Infectious Diseases in 10,000 participants. Status unknown.
17 July 2019
Quick facts
| Lead sponsor | China Academy of Chinese Medical Sciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 10,000 |
| Start date | 17 July 2019 |
| Primary completion | 17 July 2019 |
| Estimated completion | 31 December 2021 |
Drugs / interventions tested
- Pudilan Xiaoyan Oral Liquid — full drug profile →
Conditions studied
- Respiratory Infectious Diseases — all drugs for Respiratory Infectious Diseases →
Sponsor
China Academy of Chinese Medical Sciences — full company profile →
Who can join
Adults 18 to 80, any sex, with Respiratory Infectious Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To obtain the characteristics of adverse reactions/incidents, analyze the influencing factors and calculate the incidence of adverse reactions/incidents monitored by Pudilan Xiaoyan Oral Liquid in key specialties in the real world, so as to provide a basis for clinical safe and rational drug use.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Clinical Safety of Pudilan Xiaoyan Oral Liquid for the Treatment of Upper Respiratory Tract Infection in the Real World: Protocol for a Prospective, Observational, Registry Study.
Wang M, Wang L, Liu F, Chen R, et al · · 2025 · PMID 40117581 · DOI 10.2196/65789
Verify or expand the search:
- PubMed search for NCT04031651
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Infectious Diseases
Currently open trials in the same condition.
- NCT06553911 — Exploring the Application Efficacy of Artificial Intelligence (AI) Diagnostic Tools in Medical Imaging (MI) of Respirato · NA · recruiting
Other China Academy of Chinese Medical Sciences trials
Trials by the same sponsor.
- NCT07319338 — Objective Vascular Biomarkers as Triage for Depression in Chronic Atrophic Gastritis · not yet recruiting
- NCT06874738 — A Real-world Clinical Study on the Treatment of Menopausal Syndrome With Liuwei Dihuang Pills · not yet recruiting
- NCT05586048 — Effectiveness of Yiqi Fumai Lyophilized Injection for Acute Heart Failure · unknown
- NCT05138965 — the Method of Cotton Padding Promoting the Rectovaginal Fistula Surgery · completed
- NCT04932395 — Anshen Buxin Liuwei Pills for the Treatment of Cardiac Neurosis · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04031651 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by China Academy of Chinese Medical Sciences
- Last refreshed: 24 July 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04031651.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing